Quotient Sciences has been recognized as a winner of the 2024 Fierce CRO Awards category for "Innovative Solutions in Drug Development."
The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards recognize CROs that have demonstrated outstanding performance, innovation, and leadership in delivering high-quality research and development services.
Entries in the 2024 Fierce CRO Awards were judged on the ability of the applicant to demonstrate innovation, impact, measurable outcomes, sustainability, scalability, ethical and regulatory adherence. This includes:
- The level of creativity and effectiveness in advancing research and development services within the life sciences sector
- Evidence of tangible results and improvements, such as successful trials, enhanced data quality, or improved client satisfaction
- The potential for long-term impact and the ability to apply successful practices on a broader scale
- Commitment to maintaining high ethical standards and complying with relevant regulations
The company was recognized for its submission to the Innovative Solutions in Drug Development category, showcasing the impact of the Translational Pharmaceutics platform for integrated drug development to programs with Evecxia Therapeutics on EVX-101 and with Ensysce Biosciences on PF614-MPAR.
Translational Pharmaceutics® integrates real-time cGMP drug product manufacturing (including oral solid dosage forms, such as tablets and capsules), clinical testing, project management, data sciences, and related capabilities needed for a Phase I clinical trial with healthy volunteers. Each year, Quotient Sciences are consistently a leading provider of Phase I clinical trials in the UK site and in US via our global network.
Combining services and expertise as both a CDMO and CRO into one program makes it easy for clients to complete their programs, while benefitting from a single project manager for the entire process with oversight of a cross-functional project team.
"I'm proud of our teams for this accomplishment," commented Thierry Van Nieuwenhove, CEO, Quotient Sciences. "Giving our customers direct lines of communication to subject matter experts and a more integrated way to complete drug programs are two things that consistently set us apart from competitors. On each and every project that Quotient Sciences partner, we will gather a team of drug development specialists, worldwide recognized, to support our customers in every step of their development, from design to proof of concept."